Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.

Phase 1

Recruiting

• Conditions: Systemic Lupus Erythematosus
• Interventions: Drug: HC022; Drug: Placebo

• Registration Number: NCT06657703
• Lead Sponsor: HC Biopharma Inc.

Brief Summary

The primary objective of this phase Ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects. Secondary objectives of study are as follows: To estimate the PK parameters of single-ascending SC doses of HC022 in healthy subjects；To evaluate the immunogenicity of HC022 administered to healthy subjects.

Detailed Description

This is a first-in-human study of HC022 to assess safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) effects of single HC022 doses in healthy subjects.

Study Timeline

• Study First Submitted: 2024-10-18
• Study First Submitted QC: 2024-10-23
• Study First Posted: 2024-10-24
• Study Start: 2024-11-25
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-16
• Last Update Posted: 2025-04-17
• Primary Completion: 2025-08-30
• Study Completion: 2026-01-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and comply with study requirements;
2. Aged 18 to 55 years old, inclusive, male or female;
3. 3.A body weigh ≥ 50 kg for male , and a body weigh ≥ 45 kg for female, and must have a body mass index between 19 and 28 kilogram per square meter (kg/m2)；
4. Be in good health as based on medical history, physical examination, vital signs, laboratory tests, chest radiographs, abdominal ultrasound and 12-lead ECG；
5. All women of childbearing potential and all men must practice highly effective contraception during the study and for 6 months (for female) or 3 months (for male) after their dose of study treatment；

Exclusion Criteria

1. Have participated in other clinical trials within 3 months, or within the 5 half lives of the investigational drug prior to screening, whichever is longer;
2. History of or positive test results at screening for the following: for human immunodeficiency virus (HIV), hepatitis C virus antibody (HCV Ab), hepatitis B virus (defined as positive for HBsAg or HBcAb or HBeAg)；
3. History of or current diagnosis of active tuberculosis (TB), or untreated latent TB infection (LTBI) at screening；
4. History of severe herpes infection or zoster viral infection；
5. Serious infection, serious injuries, or major surgical procedures within 6 months prior to Screening；
6. History of alcohol or substance abuse, a positive urine drug or alcohol test at Day -1；
7. History of severe allergic or anaphylactic reactions or history of allergic reactions likely to be exacerbated by any component of the study drug；
8. Any disease or conditons that are not suitable for participation in this study as determined by the Investigator；

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
HC022 900mg SC	HC022	Participants will receive single subcutaneous (SC) dose of 900 mg HC022 or matching placebo on Day 1.
HC022 150mg SC	HC022	Participants will receive single subcutaneous (SC) dose of 150 mg HC022 or matching placebo on Day 1.
HC022 450mg SC	HC022	Participants will receive single subcutaneous (SC) dose of 450 mg HC022 or matching placebo on Day 1.
HC022 5mg SC	Placebo	Participants will receive single subcutaneous (SC) dose of 5 mg HC022 or matching placebo on Day 1.
HC022 50mg SC	HC022	Participants will receive single subcutaneous (SC) dose of 50 mg HC022 or matching placebo on Day 1.
HC022 50mg SC	Placebo	Participants will receive single subcutaneous (SC) dose of 50 mg HC022 or matching placebo on Day 1.
HC022 150mg SC	Placebo	Participants will receive single subcutaneous (SC) dose of 150 mg HC022 or matching placebo on Day 1.
HC022 450mg SC	Placebo	Participants will receive single subcutaneous (SC) dose of 450 mg HC022 or matching placebo on Day 1.
HC022 900mg SC	Placebo	Participants will receive single subcutaneous (SC) dose of 900 mg HC022 or matching placebo on Day 1.
HC022 5mg SC	HC022	Participants will receive single subcutaneous (SC) dose of 5 mg HC022 or matching placebo on Day 1.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	Up to 20 weeks

Secondary Outcome Measures

Name	Time	Method
Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUCinf) of HC022	Up to 20 weeks
Maximum Observed Concentration (Cmax) of HC022	Up to 20 weeks
Time to Reach Maximum Observed Concentration (Tmax) of HC022	Up to 20 weeks
Terminal Elimination Half-Life (t1/2) of HC022	Up to 20 weeks
Apparent Clearance (CL/F) of HC022	Up to 20 weeks
Apparent Volume of Distribution (Vz/F) of HC022	Up to 20 weeks
Number of Participants Who Develop Serum Anti-HC022 Antibodies	Up to 20 weeks

Trial Locations

Locations (2)

The Clinical Pharmacology Research Center of PUMCH; 🇨🇳 Peking, China

Peking Union Medical College Hospital; 🇨🇳 Peking, China